Support Services for Extrapyramidal Drugs & Parkinson’s Disease Treatment | OSMOLEX ER

SIMPLIFY THE MATH FOR YOUR ADHD PATIENTS

The first and only 72-mg methylphenidate ER tablet for appropriate patients ages 13-651,2

Learn about Methylphenidate ER 72-mg, which is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents 13 years of age and older, and adults up to the age of 65.

Support Services for Extrapyramidal Drugs & Parkinson’s Disease Treatment | OSMOLEX ER

SIMPLIFY THE MATH FOR YOUR ADHD PATIENTS

The first and only 72-mg methylphenidate ER tablet for appropriate patients ages 13-651,2

Learn about Methylphenidate ER 72-mg, which is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents 13 years of age and older, and adults up to the age of 65.

 

Indication and Important Safety Information

The 72-mg methylphenidate hydrochloride extended-release tablet USP is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents 13 years of age and older, and adults up to the age of 65.

Indication and Important Safety Information

The 72-mg methylphenidate hydrochloride extended-release tablet USP is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents 13 years of age and older, and adults up to the age of 65.


WARNING: DRUG DEPENDENCE

See full prescribing information for complete boxed warning.

Methylphenidate hydrochloride extended-release tablets should be given cautiously to patients with a history of drug dependence or alcoholism. Chronic abuse can lead to marked tolerance and psychological dependence, with varying degrees of abnormal behavior.


  • Methylphenidate hydrochloride extended-release tablets should not be used in patients with known hypersensitivity to the product; marked anxiety, tension, or agitation; glaucoma; tics or a family history or diagnosis of Tourette’s syndrome; or in patients currently using or within 2 weeks of using an MAO inhibitor
  • Methylphenidate is a stimulant. Stimulants should not be used in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious heart problems. Stimulants should be used with caution in patients with a history of high blood pressure or increased heart rate. Patients with a history of high blood pressure and for whom methylphenidate is deemed an appropriate therapy should be monitored for changes in heart rate and blood pressure
  • Use of stimulants may cause treatment-emergent psychotic or manic symptoms in patients with no prior psychiatric history. Stimulants may also exacerbate psychiatric symptoms in patients with preexisting psychiatric illness
  • Stimulants may lower the convulsive threshold in patients with epilepsy, potentially leading to seizures. Stimulants should not be taken in the presence of seizures
  • Immediate medical attention should be sought if signs or symptoms of prolonged penile erections (priapism) are observed
  • Careful observation for peripheral vasculopathy in extremities, including but not limited to Raynaud’s phenomenon, is necessary during treatment with ADHD stimulants
  • Pediatric patients should be monitored for height and weight at age-appropriate intervals for potential long-term suppression of growth
  • Difficulties with accommodation and blurring of vision have been reported with stimulant treatment. Patients with a history of glaucoma should not take stimulants
  • This extended-release tablet is nondeformable and does not appreciably change in shape in the GI tract; therefore, gastrointestinal obstruction may potentially occur in patients with prior history of GI narrowing
  • Periodic complete blood count (CBC) with differential and platelet counts are advised during prolonged therapy
  • The most common adverse reaction in double-blind clinical trials (>5%) in children and adolescents was upper abdominal pain. The most common adverse reactions in double-blind clinical trials (>5%) in adult patients were decreased appetite, headache, dry mouth, nausea, insomnia, anxiety, dizziness, weight decrease, irritability, and hyperhidrosis

Please click here for full Prescribing Information, including Boxed Warning.


References

  1. Methylphenidate hydrochloride extended-release tablets [package insert]. Trigen Laboratories, LLC; 2017.
  2. Data on file, Osmotica Pharmaceutical US LLC.
  3. US Food and Drug Administration. Draft Guidance on Methylphenidate Hydrochloride. Revised November 2014. Accessed July 2018.